Reading CSBR? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track CSBR free→Reading CSBR? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track CSBR free→NASDAQHealth CareBiotechnologySnapshot 2026-06-15
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
Recent financial performance is strong, and management's recent track record has been steady. The company was unprofitable over the past year, so its earnings quality can't be assessed. Peer multiples imply a price about 84% above where it trades (it looks cheap on this basis); the read is cheap, value-trap risk, as it trades below peer multiples, but recent financials are weak or earnings quality is fragile. If CSBR cuts guidance on the next call, that's a meaningful negative. This read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 3 valuation methods, at three horizons. Current price $6.34. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $6.50 CSBR trades at 2× p/s, below its 10× p/s peer median. Our $42 fair value sits above the price; low confidence. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The price implies about 84% below a flat-multiple fair value, below our forecast of about -7%. This describes what's priced in, not a forecast of the move.
TTM earnings are negative, so the read leans on sales- and cash-flow-based methods rather than P/E. This is a data condition, not a forward call.
Only a turbulent sector regime (Heating) — not the full expensive x weak x turbulent stack.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 59% of the time over the next year (vs 52% for the rest of the cohort, n=2344).
Over the trailing year it converted -1.93x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, Fed net liquidity, long-term interest rates, real (inflation-adjusted) rates.
2 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated stable grew net income 56% of the time over the next year (vs 52% for the rest of the cohort, n=618).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$167.
How much price usually moves either way.
On a bad day, this stock has moved -$590.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $3,670.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-15
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: If healthcare sector growth picks up, it may help Champions Oncology's performance. The sector is currently in a maturing phase.
Confirms:Healthcare sector revenue growth speeds up to 10% or more.
Disproves:Healthcare sector revenue growth slows down below 10%.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for CSBR yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On March 24, 2026, the Board of Directors (the “Board”) of Champions Oncology, Inc. (the “Company”) accepted the resignation of Dr. Philip Breitfeld as a member of the Board and appointed Dr. Brian Alexander as a director of the Company to fill the vacancy created by Dr. Breitfeld’s resignation. Dr. Breitfeld’s decision to resign was not due to any…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Roughly priced in line with peers.
Self-history needs ~20 months of data.
Trailing four: 2025-Q3, 2026-Q1, 2026-Q2, 2026-Q3
A side-by-side read on sector standing, valuation, and risk versus Biotechnology.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
CSBR Champions Oncology Inc | Above typical Show detailsSector percentile: 80 of 100 | inexpensive | high |
ABBV AbbVie | Above typical Show detailsSector percentile: 85 of 100 | fair | low |
AMGN Amgen | Above typical Show detailsSector percentile: 77 of 100 | full | moderate |
GILD Gilead Sciences | Above typical Show detailsSector percentile: 100 of 100 | fair | moderate |
VRTX Vertex Pharmaceuticals | Above typical Show detailsSector percentile: 80 of 100 | expensive | moderate |
Not investment advice. As of 2026-06-15.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-15.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Management aims to achieve positive adjusted EBITDA for the full fiscal year.
Stated in 3 of last 3 quarters. Despite the goal of achieving positive adjusted EBITDA, the company reported a net income of -$279,000 in 2026-Q3, down from $268,000 in 2026-Q2. Persistent statement, limited substantive delivery this quarter.
“Company remains on track to deliver year-over-year revenue growth and positive adjusted EBITDA for the fiscal year.”
“We remain on track to deliver year-over-year revenue growth and to achieve positive adjusted EBITDA for the full fiscal year.”
“We anticipate continued topline expansion and margin improvement driven by a healthy services pipeline.”
Management is focused on driving continued revenue growth through a strong pipeline and data monetization.
Stated in 3 of last 3 quarters. Revenue grew from $12.36M in 2025-Q4 to $16.56M in 2026-Q3, indicating a positive trajectory. Management's focus on revenue growth is delivering results.
“Company remains on track to deliver year-over-year revenue growth and positive adjusted EBITDA for the fiscal year.”
Management plans to expand proprietary data offerings to drive growth.
Stated in 2 of last 3 quarters. While management emphasizes expanding proprietary data offerings, the financials do not provide specific data-related revenue figures. Recurring focus, narrow delivery so far.
“We anticipate continued topline expansion and margin improvement driven by a healthy services pipeline.”
Why it matters: The earnings report will show if Champions Oncology is getting better financially. Investors want to see signs of recovery from losses.
Confirms one read:Earnings report shows revenue growth above 10% year over year.
Confirms the other:Earnings report shows revenue decline or losses continue.
in this Current Report shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
in this Current Report shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
in this Current Report shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On July 18, 2025, Champions Oncology, Inc. (the “Company”) announced the hiring and appointment of Robert Brainin to serve as the Company’s Chief Executive Officer, effective as of August 25, 2025. Mr. Brainin, age 54, has served as a member of the Company's Board of Directors since February 2021 and will remain a Director following his appointment…
“We remain on track to deliver year-over-year revenue growth and to achieve positive adjusted EBITDA for the full fiscal year.”
“We anticipate continued topline expansion and margin improvement driven by a healthy services pipeline.”
“We’re confident in our ability to drive continued revenue growth and further accelerate the monetization of our data offering.”